CAVADEXTRIN® reduces atherosclerosis
CAVADEXTRIN® captures cholesterol and transports the cholesterol out of the body in the urine.
What is CAVADEXTRIN®
In 2016, German scientists discovered that a compound “Cyclodextrin” reduced arterial plaque in mice.
Cholrem Pty Ltd researched cyclodextrins and engineered a specific cyclodextrin with enhanced cholesterol transport capabilities. This new cyclodextrin "CAVADEXTRIN®" is a ring-shaped structure made from starch.
CAVADEXTRIN® is only several atoms wide and has a cavity in the middle. The outside of the ring is attracted to water and the inside cavity is attracted to oils and lipids (like cholesterol).
When CAVADEXTRIN® circulates around the vascular system, cholesterol is sucked into the cavity and the cholesterol binds with the CAVADEXTRIN® and is transported out of the body via the urine.
CAVADEXTRIN reverses Heart Disease
CAVADEXTRIN® reduces lipid levels and arterial plaque within 4 weeks.
The only cyclodextrin proven safe in the treatment of atherosclerosis
Start your treatment today
Remchol for home use
CAVADEXTRIN® can only be absorbed into the blood stream when administered as an IV or as an enema.
RemChol delivers CAVADEXTRIN® via an enema.
Each tube contains 8 grams of CAVADEXTRIN® with over 2 grams absorbed into the blood stream with every treatment.
Remchol tubes can be administered as often as twice a day.
Cyclodextrin reprogrammed the cells in plaques, leading to increased transport of the dissolved cholesterol away from the plaques...
Cyclodextrin dissolves cholesterol crystals and reduces atherosclerotic plaques...
can actually solubilize cholesterol and dissolve the plaques...
Soaked up cholesterol and removed it...
Norwegian University of Science and Technology
have the potential in lowering deaths caused by atherosclerosis...
CAVADEXTRIN® removes plaque and cholesterol
plaque reduced in just 4 weeks
A recent study by the University Hospital in Bonn, Germany discovered that cyclodextrin melts away cholesterol crystals (the main cause of arterial plaque that clogs arteries) and reduced existing plaque within just 4 weeks. The cyclodextrin bound to and dissolved the cholesterol crystals from the plaque of mice, leading to transport of the dissolved cholesterol away from the plaques. The same effects were seen in human plaque samples treated with cyclodextrin.Article : Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming
Improve Liver function
Another study by the University of Texas Southwestern Medical Center, Dallas, Texas, shows the treatment of Npc1-deficient mice slows cholesterol sequestration in major organs and improves liver function. This study shows that cyclodextrin is effective in mobilizing entrapped cholesterol in late stage NPC disease leading to improved liver function.Article : Systemic administration of 2-hydroxypropyl-B-cyclodextrin to symptomatic Npc1-deficient mice slows cholesterol sequestration in the major organs and improves liver function.
Cyclodextrin has shown to extend lifespan by almost 10% in mice
Mice treated with CAVADEXTRIN® showed higher neurological scores than compared with the mice given saline only..
Mice on CAVADEXTRIN® lived 10% longer.
CAVADEXTRIN® cleares the vascular system and can extend lifespan.
In 2014 at the University of Texas Southwest Medical Center, a study was conducted on the effects of Cyclodextrin administered to mice.
They studied the lifespan of mice treated systemically with either saline or Cyclodextrin at weekly
intervals starting at 49 days of age until death. In each case, half of the males and females were
given Cyclodextrin and the remaining mice received only saline.
During the study, the mice were graded on their neurological function. There were no gender related differences in the neurological scores. This score, which broadly measures neurological function, declines as the animal’s condition deteriorates.
It is clear that Cyclodextrin treated mice showed higher neurological scores than compared with the mice given saline only.
All the mice given saline only had died by 98 days whereas the majority of those receiving Cyclodextrin died in the week following. This shows an almost 10% improvement in lifespan.
The human trial of CAVADEXTRIN conducted by Cholrem has consistantly shown the scientific evidence proving the benefits of Cyclodextrin on mice also has simular benefits on humans. It would be fair to assume that based on the science, humans treated with CAVADEXTRIN would also experience a simular benefit of lifespan extention as the mice.
Molecular mechanism of cyclodextrin mediated cholesterol extraction
Rationale for Therapeutic Use of Lipid Transport Mediators in Renal Disease
Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury.
Systemic and renal lipids in kidney disease development and progression
Metabolism, energetics, and lipid biology in the podocyte - cellular cholesterol-mediated glomerular injury.
Lipid biology of the podocyte--new perspectives offer new opportunities.
Renal lipid metabolism and lipotoxicity.
Cyclodextrins and Non-renal Diseases
Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming.
Weekly Treatment of 2-Hydroxypropyl-β-cyclodextrin Improves Intracellular Cholesterol Levels in LDL Receptor Knockout Mice.
Beta cyclodextrins bind, stabilize, and remove lipofuscin bisretinoids from retinal pigment epithelium.
Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease.
Cyclodextrins and Renal Disease
Cyclodextrin Protects Podocytes in Focal Segmental Glomerulosclerosis (FSGS)
Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis.
Cyclodextrin improves renal function in experimental alport syndrome.